Alireza Pishgahi on Attenuation of Memory Impairment After Ischemia
Alireza Pishgahi, President at Novagena, shared on LinkedIn:
”I am proud to announce that our valuable study on Stroke Regeneration have been published.
Looking forward to bring it from bench to bedside.”
Stroke is the second leading cause of death globally, placing a heavy burden on both public health and economies.
This study explored the impact of autologous conditioned serum (ACS) on memory and related molecular factors in a mouse model of ischemic stroke.
The findings suggest that intranasal ACS treatment after stroke improves memory, likely by elevating IGF-1 levels, reducing inflammation via IL-1β inhibition, and regulating tau protein levels.
Read the full article here.
Article: Intranasal Autologous Conditioned Serum Attenuates Memory Impairment After mPFC Ischemia in Mice
Authors: Sareh Kazmi, Neda Yazdanfar, Fatemehsadat Seyedaghamiri, Alireza Pishgahi, Mehdi Yousefi, Tahereh Ghadiri, Saeed Sadigh-Eteghad, Mehdi Farhoudi
Stay updated on all scientific advances with Hemostasis Today.
-
Jan 25, 2026, 15:57Céline Chapelle Shares Clinical Predictors From the API-CAT Trial
-
Jan 25, 2026, 15:42Francesco Lo Monaco on Heart Disease Starting Quiet While Your Labs Speak First
-
Jan 25, 2026, 15:25Muhammad Ibrahim on Efficacy and Safety of Extended DOACs Use in VTE
-
Jan 25, 2026, 15:08Tushar Pandey on Managing Thrombotic Thrombocytopenic Purpura
-
Jan 25, 2026, 14:55Carolina Contreras Cuevas Shares a Nationwide Study on VTE in PAD
-
Jan 25, 2026, 14:40Jeannie Devereaux Links PRP and Physical Therapy
-
Jan 25, 2026, 14:25Heghine Khachatryan on Anticoagulation After AFib Ablation: New Evidence from NEJM
-
Jan 25, 2026, 12:42Lale Tokgözoğlu on Cardiovascular Risk Factors in Women
-
Jan 25, 2026, 12:32Dino Mehic on Bleeding Assessment Tools and QoL in BDUC